CCO Oncology Podcast artwork

Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

CCO Oncology Podcast

English - November 30, 2023 14:09 - 19 minutes - 18 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: A Year in Review and a Look to the Future: BTKi in CLL and MCL
Next Episode: Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

Navitoclax (BCL-XL/BCL-2 inhibitor)Pelabresib (BET inhibitor)Imetelstat (telomerase inhibitor)Luspatercept (erythroid maturation agent)Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV